Brokerages expect that Corium International Inc (NASDAQ:CORI) will announce earnings per share (EPS) of ($0.43) for the current quarter, according to Zacks. Two analysts have made estimates for Corium International’s earnings, with estimates ranging from ($0.46) to ($0.40). Corium International reported earnings of ($0.46) per share in the same quarter last year, which indicates a positive year over year growth rate of 6.5%. The firm is scheduled to report its next quarterly earnings report after the market closes on Thursday, February 8th.
According to Zacks, analysts expect that Corium International will report full year earnings of ($1.47) per share for the current year, with EPS estimates ranging from ($1.58) to ($1.33). For the next fiscal year, analysts expect that the company will post earnings of ($1.33) per share, with EPS estimates ranging from ($1.69) to ($0.94). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Corium International.
Corium International (NASDAQ:CORI) last posted its earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.07. Corium International had a negative return on equity of 482.64% and a negative net margin of 149.99%.
Corium International (NASDAQ:CORI) opened at $12.25 on Wednesday. The company has a debt-to-equity ratio of 2.41, a quick ratio of 2.60 and a current ratio of 2.70. The firm has a market capitalization of $433.80, a PE ratio of -7.34 and a beta of 1.59. Corium International has a twelve month low of $2.72 and a twelve month high of $13.93.
In related news, major shareholder Perceptive Advisors Llc bought 50,350 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were acquired at an average price of $11.83 per share, with a total value of $595,640.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of Corium International stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $10.96, for a total value of $5,480,000.00. The disclosure for this sale can be found here. Insiders own 30.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund acquired a new stake in shares of Corium International in the second quarter valued at about $158,000. California State Teachers Retirement System acquired a new stake in shares of Corium International in the second quarter valued at about $263,000. Teachers Advisors LLC acquired a new position in Corium International during the second quarter worth approximately $272,000. California Public Employees Retirement System acquired a new position in Corium International during the fourth quarter worth approximately $310,000. Finally, TIAA CREF Investment Management LLC acquired a new position in Corium International during the second quarter worth approximately $411,000. 89.15% of the stock is currently owned by institutional investors and hedge funds.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.